hit counter
Aileron Therapeutics, Inc. (ALRN) Stock News Sentiment & Price - Sentifly
ALRN - Sentifly


Profile

Watchlist

Your watchlist is empty. Go add some tickers to it!



Aileron Therapeutics, Inc. (ALRN)

USA
Biotechnology
NASDAQ
ALRN Price and Sentiment
1MO
1D
Positive, Negative
Loading chart...
ALRN Latest news
GlobeNewsWire
Neutral
Aileron Therapeutics Presents Data at AACR-NCI-EORTC International Conference Demonstrating ALRN-6924's Activity as Radioprotective Agent in Preclinical Models of Acute Radiation-Induced Toxicity
2021-10-07 09:22

-- Aileron is currently developing ALRN-6924 as a novel, selective chemoprotective agent for patients with p53-mutated cancer undergoing chemotherapy -- -- Preclinical data demonstrated ALRN-6924's activation of p21-induced cell cycle arrest in murine bone marrow cells and epithelial mucosa cells in the gastrointestinal (GI) tract --

Benzinga
Negative
Aileron Stock Is Trading Lower After Data Presentation For Chemoprotective Agent
2021-09-16 14:33

Aileron Therapeutics Inc (NASDAQ: ALRN) presented new clinical data at the European Society of Medical Oncology ( ESMO21 ) Virtual Congress 2021 for ALRN-6924, a chemoprotective agent.  Aileron is developing ALRN-6924 to selectively protect healthy cells in patients with cancers that harbor p53 mutations to reduce or eliminate chemotherapy-induced side effects while preserving chemotherapy's attack on cancer cells.

GlobeNewsWire
Neutral
Aileron Therapeutics Presents New Clinical Data at ESMO Virtual Congress 2021 Supporting ALRN-6924's Best-in-Class Potential as a Chemoprotective Agent
2021-09-16 08:15

BOSTON, Sept. 16, 2021 (GLOBE NEWSWIRE) -- Aileron Therapeutics (Nasdaq: ALRN), a chemoprotection oncology company focused on fundamentally transforming the experience of chemotherapy for cancer patients, today presented new clinical data at the European Society of Medical Oncology (ESMO) Virtual Congress 2021 supporting ALRN-6924's best-in-class potential as a chemoprotective agent. The company presented final results from its completed Phase 1b trial of ALRN-6924 in patients with small cell lung cancer (SCLC) receiving second-line topotecan treatment, which demonstrated ALRN-6924's ‘triple-play efficacy' for the reduction of neutropenia, thrombocytopenia and anemia, as well as a reduction of platelet and red blood cell transfusions, as compared to historical controls. Aileron today also presented preliminary results from its ongoing Phase 1 pharmacology study of ALRN-6924, which confirmed 0.3 mg/kg as the optimal dose for ALRN-6924 and confirmed its novel p53 biomarker-driven mechanism of action, as well as

GlobeNewsWire
Neutral
Aileron Therapeutics to Present New Clinical Data at ESMO Virtual Congress 2021 Supporting Novel, Selective Chemoprotective Agent ALRN-6924
2021-09-10 08:30

BOSTON, Sept. 10, 2021 (GLOBE NEWSWIRE) -- Aileron Therapeutics (Nasdaq: ALRN), a chemoprotection oncology company focused on fundamentally transforming the experience of chemotherapy for cancer patients, today announced two upcoming poster presentations at the European Society of Medical Oncology (ESMO) Virtual Congress 2021, which is being held September 16-21, 2021. In these posters, Aileron will present preliminary data from its ongoing Phase 1 study of ALRN-6924 in healthy volunteers and final data from its completed Phase 1b study of ALRN-6924 in patients with small cell lung cancer (SCLC) receiving second-line topotecan treatment. Aileron is developing ALRN-6924 to selectively protect healthy cells in patients with cancers that harbor p53 mutations to reduce or eliminate chemotherapy-induced side effects while preserving chemotherapy's attack on cancer cells, an emerging concept known as chemoprotection. ALRN-6924, a first-in-class MDM2/MDMX dual inhibitor, is designed to activate p53, which in turn up

GlobeNewsWire
Neutral
Aileron Therapeutics to Present at Upcoming H.C. Wainwright Virtual Global Investment Conference
2021-09-07 16:05

BOSTON, Sept. 07, 2021 (GLOBE NEWSWIRE) -- Aileron Therapeutics (Nasdaq: ALRN), a chemoprotection oncology company focused on fundamentally transforming the experience of chemotherapy for cancer patients, today announced that Manuel Aivado, M.D., Ph.D., President and Chief Executive Officer, will give a corporate presentation at the upcoming H.C. Wainwright Virtual Global Investment Conference, taking place September 13 – 15, 2021. Dr. Aivado's presentation will include an update on the company's progress advancing ALRN-6924 as a selective chemoprotective agent for patients with p53-mutated cancers regardless of type of cancer or chemotherapy.

GlobeNewsWire
Neutral
Aileron Therapeutics Presents Initial Findings from Ongoing Healthy Volunteer Study of ALRN-6924 at ISEH 50th Annual Scientific Meeting
2021-08-27 07:45

BOSTON, Aug. 27, 2021 (GLOBE NEWSWIRE) -- Aileron Therapeutics (Nasdaq: ALRN), a chemoprotection oncology company focused on fundamentally transforming the experience of chemotherapy for cancer patients, today announced a poster presentation showcasing initial findings from its ongoing study of ALRN-6924 in healthy volunteers at the International Society for Experimental Hematology (ISEH) 50th Annual Scientific Meeting, which is currently underway. The initial findings demonstrated that a 0.3 mg/kg dose of ALRN-6924 has been very well tolerated and resulted in p53-mediated induction of the cell cycle inhibitor p21 in healthy, normal bone marrow cells without concurrent induction of apoptosis. The poster can be viewed on Aileron's website here.

GlobeNewsWire
Neutral
Aileron Therapeutics to Participate in Fireside Chat at the William Blair Biotech Focus Conference 2021
2021-07-08 08:15

BOSTON, July 08, 2021 (GLOBE NEWSWIRE) -- Aileron Therapeutics (NASDAQ:ALRN), a chemoprotection oncology company focused on fundamentally transforming the experience of chemotherapy for cancer patients, announced today that Manuel Aivado, M.D., Ph.D., President and Chief Executive Officer, is scheduled to participate in a fireside chat at the William Blair Biotech Focus Conference 2021 at 3:00 p.m. ET on Thursday, July 15, 2021. Management will also be available for virtual 1x1 meetings from July 14-15.

Benzinga
Positive
Aileron Launches Early-Stage Study For Chemoprotective Candidate In Lung Cancer Settings
2021-07-01 13:39

Aileron Therapeutics Inc (NASDAQ: ALRN) has initiated Phase 1b trial of ALRN-6924 as a chemoprotective agent to treat patients with non-small cell lung cancer undergoing chemotherapy.  Aileron plans to enroll 60 patients with advanced p53-mutated NSCLC undergoing treatment with first-line carboplatin plus pemetrexed with or without immune checkpoint inhibitors.

GlobeNewsWire
Neutral
Aileron Therapeutics to be Added to the Russell Microcap® Index
2021-06-24 07:00

BOSTON, June 24, 2021 (GLOBE NEWSWIRE) -- Aileron Therapeutics (NASDAQ:ALRN), a chemoprotection oncology company focused on fundamentally transforming the experience of chemotherapy for cancer patients, announced today that it is set to join the Russell Microcap® Index at the conclusion of the 2021 Russell indexes annual reconstitution, effective after the U.S. market opens on June 28, 2021.

Loading more news...